The effect on left ventricular performance of nifedipine and metoprolol singly and together in exercise-induced

European Heart Journal
|January 1, 1984
PubMed

Insights

Combining nifedipine and metoprolol offers hemodynamic advantages for patients with coronary heart disease and impaired left ventricular function. This combination effectively reduces heart rate and blood pressure, improving anginal symptoms.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Clinical concerns exist regarding combined beta-blocker and calcium channel blocker effects in patients with coronary heart disease and impaired left ventricular function.
  • Negative inotropic effects of these drug classes can be deleterious.

Purpose of the Study:

  • To investigate the hemodynamic effects of nifedipine and metoprolol, alone and in combination, in patients with severe angina and coronary artery disease.
  • To assess the impact on left ventricular function and oxygen consumption.

Main Methods:

  • 20 patients with severe angina and documented coronary artery disease were studied.
  • Hemodynamic parameters were measured at rest and during exercise after administration of sublingual nifedipine (20 mg) and intravenous metoprolol (10 mg), singly and in combination.
  • Plasma drug concentrations were within therapeutic ranges.

Main Results:

  • Nifedipine reduced systemic arterial pressure and vascular resistance, increasing heart rate and cardiac output.
  • Metoprolol reduced blood pressure, heart rate, and cardiac output, increasing left heart filling pressure.
  • The combination largely offset negative inotropic effects and reflex tachycardia, reducing determinants of left ventricular oxygen consumption (heart rate, blood pressure) with a minor increase in filling pressure.

Conclusions:

  • The combination of nifedipine and metoprolol demonstrated superior hemodynamic advantages compared to either drug alone in patients with coronary heart disease and depressed left ventricular function.
  • This combination may improve anginal symptoms by reducing left ventricular oxygen demand.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...